This research trial studies metabolic changes in blood samples from patients with acute myeloid leukemia. Studying samples of blood from patients with acute myeloid leukemia in the laboratory may help doctors learn more about cancer and the development of drug resistance.
I. To determine the metabolic adaptations that occur following exposure to standard chemotherapeutic agents using peripheral blood mononuclear cells from acute myeloid leukemia (AML) patients.
OUTLINE:
Patients undergo collection of peripheral blood mononuclear cell (PBMC) samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.
Patients scheduled to initiate chemotherapy for either an initial diagnosis of AML or relapsed AML Starting the initial induction phase of therapy Exposure to hydroxyurea is acceptable but must be noted at the time of sample collection Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent
Exclusion Criteria:
Received at least one dose of chemotherapy during the current cycle (excluding hydroxyurea).
